INTERVENTION 1:	Intervention	0
Zoledronic Acid	Intervention	1
zoledronic acid	CHEBI:46557	0-15
4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)	Intervention	2
disease	DOID:4,OGMS:0000031	57-64
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Diagnosis of localized breast cancer	Eligibility	1
localized	HP:0012838,PATO:0000627	13-22
breast cancer	DOID:1612	23-36
Stage I-IIIA disease	Eligibility	2
disease	DOID:4,OGMS:0000031	13-20
Adequately treated breast cancer	Eligibility	3
breast cancer	DOID:1612	19-32
No clinical or radiological evidence of recurrent or metastatic disease	Eligibility	4
recurrent	HP:0031796	40-49
disease	DOID:4,OGMS:0000031	64-71
Baseline total lumbar spine or femoral neck bone mineral density T-score < -2.0 standard deviation (e.g., a patient with a T score of -2.1 is eligible)	Eligibility	5
neck	GO:0044326,UBERON:0000974	39-43
bone mineral density	CMO:0001226	44-64
standard deviation	BAO:0002176	80-98
patient	HADO:0000008,OAE:0001817	108-115
t	CHEBI:36371,BAO:0001260	9-10
t	CHEBI:36371,BAO:0001260	11-12
t	CHEBI:36371,BAO:0001260	62-63
t	CHEBI:36371,BAO:0001260	65-66
t	CHEBI:36371,BAO:0001260	81-82
t	CHEBI:36371,BAO:0001260	94-95
t	CHEBI:36371,BAO:0001260	110-111
t	CHEBI:36371,BAO:0001260	114-115
t	CHEBI:36371,BAO:0001260	118-119
t	CHEBI:36371,BAO:0001260	123-124
Hormone-receptor status:	Eligibility	6
Estrogen receptor and/or progesterone receptor-positive breast cancer	Eligibility	7
estrogen	CHEBI:50114,BAO:0000760	0-8
receptor	BAO:0000281	9-17
receptor	BAO:0000281	38-46
progesterone	CHEBI:17026	25-37
breast cancer	DOID:1612	56-69
PATIENT CHARACTERISTICS:	Eligibility	8
patient	HADO:0000008,OAE:0001817	0-7
Female	Eligibility	9
female	PATO:0000383	0-6
Postmenopausal, defined by 1 of the following criteria:	Eligibility	10
Age > 55 years with cessation of menses	Eligibility	11
age	PATO:0000011	0-3
Age  55 years with spontaneous cessation of menses for > 1 year	Eligibility	12
age	PATO:0000011	0-3
year	UO:0000036	8-12
year	UO:0000036	59-63
Age  55 years with spontaneous cessation of menses for  1 year, but amenorrheic (e.g., spontaneous or secondary to hysterectomy), AND has postmenopausal estradiol levels	Eligibility	13
age	PATO:0000011	0-3
year	UO:0000036	8-12
year	UO:0000036	58-62
estradiol	CHEBI:23965	153-162
Bilateral oophorectomy	Eligibility	14
bilateral	HP:0012832	0-9
ECOG performance status 0-2	Eligibility	15
Life expectancy  5 years	Eligibility	16
WBC  3,000/mm³ OR granulocyte count  1,500/mm³	Eligibility	17
Platelet count  100,000/mm³	Eligibility	18
platelet count	CMO:0000029	0-14
Alkaline phosphatase  3 times upper limit of normal (ULN)	Eligibility	19
phosphatase	GO:0016791,BAO:0000295	9-20
AST  3 times ULN	Eligibility	20
Creatinine < 2.0 mg/dL	Eligibility	21
creatinine	CHEBI:16737	0-10
Creatinine clearance  45 mL/min	Eligibility	22
creatinine clearance	CMO:0000765	0-20
No hypercalcemia (i.e., calcium level > 1 mg/dL above ULN) OR hypocalcemia (i.e., calcium level > 0.5 mg/dL below lower limit of normal) within the past 6 months	Eligibility	23
hypercalcemia	HP:0003072,DOID:12678	3-16
calcium	CHEBI:22984,BAO:0000874	24-31
calcium	CHEBI:22984,BAO:0000874	82-89
hypocalcemia	HP:0002901	62-74
No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix	Eligibility	24
skin cancer	DOID:4159	98-109
carcinoma	HP:0030731,DOID:305	113-122
No other nonmalignant systemic diseases, including any of the following:	Eligibility	25
Uncontrolled infection	Eligibility	26
Uncontrolled diabetes mellitus	Eligibility	27
diabetes mellitus	HP:0000819,DOID:9351	13-30
Uncontrolled thyroid dysfunction	Eligibility	28
Disease affecting bone metabolism (hyperparathyroidism, hypercortisolism, Paget's disease, osteogenesis imperfecta)	Eligibility	29
disease	DOID:4,OGMS:0000031	0-7
disease	DOID:4,OGMS:0000031	82-89
hyperparathyroidism	HP:0000843,DOID:13543	35-54
osteogenesis imperfecta	DOID:12347	91-114
Malabsorption syndrome	Eligibility	30
malabsorption	HP:0002024	0-13
syndrome	DOID:225	14-22
No uncontrolled seizure disorders associated with falls	Eligibility	31
seizure	HP:0001250	16-23
falls	HP:0002527	50-55
No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium, or vitamin D	Eligibility	32
hypersensitivity	GO:0002524,DOID:1205	9-25
letrozole	CHEBI:6413	67-76
calcium	CHEBI:22984,BAO:0000874	78-85
vitamin d	CHEBI:27300	90-99
No concurrent active dental problems, including any of the following:	Eligibility	33
active	PATO:0002354	14-20
Infection of the teeth or jawbone (maxillary or mandibular)	Eligibility	34
Dental or fixture trauma	Eligibility	35
Prior or current diagnosis of osteonecrosis of the jaw	Eligibility	36
osteonecrosis	DOID:10159	30-43
Exposed bone in the mouth	Eligibility	37
mouth	UBERON:0000165	20-25
Slow healing after dental procedures	Eligibility	38
No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following:	Eligibility	39
contraindication	OAE:0000055	3-19
History of surgery at the lumbosacral spine, with or without implantable devices	Eligibility	40
history	BFO:0000182	0-7
surgery	OAE:0000067	11-18
Scoliosis with a Cobb angle > 15 degrees at the lumbar spine	Eligibility	41
scoliosis	HP:0002650,DOID:0060249	0-9
Immobility, hyperostosis, or sclerotic changes at the lumbar spine, or evidence of sclerotic abdominal aorta sufficient to interfere with DXA scan	Eligibility	42
hyperostosis	HP:0100774,DOID:205	12-24
abdominal aorta	UBERON:0001516	93-108
Disease of the spine that would preclude the proper acquisition of a lumbar spine DXA	Eligibility	43
disease	DOID:4,OGMS:0000031	0-7
No condition that would preclude study follow-up or compliance	Eligibility	44
condition	PDRO:0000129	3-12
No psychiatric illness that would preclude giving informed consent	Eligibility	45
PRIOR CONCURRENT THERAPY:	Eligibility	46
More than 3 weeks since prior and no other concurrent oral bisphosphonates	Eligibility	47
No prior intravenous bisphosphonates	Eligibility	48
No prior aromatase inhibitor therapy	Eligibility	49
inhibitor	CHEBI:35222	19-28
More than 6 months since prior anabolic steroids or growth hormone	Eligibility	50
growth hormone	CHEBI:37845,GO:0005131	52-66
More than 2 weeks since prior and no concurrent inhibitor of osteoclastic bone resorption (e.g., calcitonin, mithramycin, or gallium nitrate)	Eligibility	51
inhibitor	CHEBI:35222	48-57
bone resorption	GO:0045453	74-89
calcitonin	CHEBI:3306	97-107
mithramycin	CHEBI:31856	109-120
nitrate	CHEBI:17632	133-140
More than 30 days since prior systemic investigational drug and/or device	Eligibility	52
drug	CHEBI:23888	55-59
More than 7 days since prior topical investigational drug	Eligibility	53
drug	CHEBI:23888	53-57
More than 6 weeks since prior and no concurrent dental or jaw surgery (e.g., extraction, implants)	Eligibility	54
surgery	OAE:0000067	62-69
Concurrent short-term corticosteroid therapy allowed	Eligibility	55
corticosteroid	CHEBI:50858	22-36
No concurrent sodium fluoride, parathyroid hormone, or tibolone	Eligibility	56
sodium fluoride	CHEBI:28741	14-29
hormone	CHEBI:24621	43-50
tibolone	CHEBI:32223	55-63
No other concurrent investigational drug or device	Eligibility	57
drug	CHEBI:23888	36-40
Outcome Measurement:	Results	0
Average Intra-patient Change in Total Lumbar Spine (L1 to L4) Bone Mineral Density (BMD)	Results	1
bone mineral density	CMO:0001226	62-82
Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value.	Results	2
Time frame: Baseline and 1 year	Results	3
time	PATO:0000165	0-4
year	UO:0000036	27-31
Results 1:	Results	4
Arm/Group Title: Zoledronic Acid	Results	5
zoledronic acid	CHEBI:46557	17-32
Arm/Group Description: 4 mg intravenously over 15 minutes every 6 months (until disease progression or for 5 years)	Results	6
disease	DOID:4,OGMS:0000031	80-87
Overall Number of Participants Analyzed: 30	Results	7
Mean (95% Confidence Interval)	Results	8
mean	BAO:0002173	0-4
Unit of Measure: Percentage of the baseline value  2.66        (1.27 to 4.62)	Results	9
Adverse Events 1:	Adverse Events	0
Total: 1/52 (1.92%)	Adverse Events	1
Musculoskeletal disorder 1/52 (1.92%)	Adverse Events	2
disorder	OGMS:0000045	16-24
